摘要
目的:研究肝脏病人血浆凝血酶原的变化,并探讨其临床意义。方法:急性黄疸型乙型肝炎20例,肝硬化10例,原发性肝癌15例,对照组30例,用Ecarin-发色底物法检测其血浆中全凝血酶原量与吸附后凝血酶原量,PT用一期法测定。结果:所有患者PT延长,肝炎与肝硬化病人全凝血酶原量降低,肝癌病人增高;吸附后凝血酶原在肝癌病人增高显著,阳性为93.33%。结论:肝炎与肝硬化病人PT延长与全凝血酶原下降,可评估疾病严重程度并作为治疗监测。异常凝血酶原增高可用作原发性肝癌的筛选诊断。
Objective: To study the change of prothrombin in plasma on patients with liver disease and research its clinic significance. Methods: Acute jaundice B type hepatitis 20 cases, hepatic cirrhosis 10 cases, primary hep-atoma 15 cases, and control group 30 cases.The PT with one step method ,total prothrombin and after sbsorb prothrombin were deteminted with Ecarin-Chromogenic peptide substrate method. Results: All patients PT higher than controls. Total prothrombin are decreased in patients with hepatitis and cirrhosis, but increased in patients with primary hepatoma. After abosorb prothrombin(Abnormal prothrombin) are significant higher in primary depatoma than in control. Conclusion: PT delay and total prothrombin decreased in patients with hepatitis and cirrhosis and clear up serious degree of disease and monitor for treatment. Abnormal protherombin obvious increased can act as screeing diagnosis for primary hepatoma.
出处
《血栓与止血学》
2003年第3期106-107,共2页
Chinese Journal of Thrombosis and Hemostasis